AMGN
AMGEN INC
Nasdaq: AMGN · Thousand Oaks, CA · Healthcare
$344.57-1.17 (-0.34%)Closed
Market Cap$185.96B
Cash$12.04Bmost recent
Runwayprofitable
P/E (TTM)24.2EPS $14.23
52-Wk Range$264.49 – $385.25
Avg Volume2.6M3-month
Price & Trading Activity

Daily close with catalyst overlays and trading volume

$344.57+20.2%
Pipeline

Drug candidates sponsored by AMGEN · ClinicalTrials.gov

69 drugs · 100 trials
PhaseDrug / CandidateIndicationsStatusNext CompletionTrials
Phase 4Traditional Vitamin D Therapy
Hyperparathyroidism, Secondary
Completed
2012-07-17past
1
Phase 4Etanercept via Autoinjector A
Rheumatoid Arthritis+1 more
Completed
2014-03-04past
1
Phase 4800 mg ibuprofen/26.6 mg famotidine
Juvenile Idiopathic Arthritis
Completed
2015-03past
1
Phase 4cinacalcet
Chronic Kidney Disease+12 more
Completed
2015-09-23past
3
Phase 4Etanercept
Plaque Psoriasis+2 more
Completed
2015-11past
5
Phase 4AMG 073
Hyperparathyroidism+1 more
Completed—1
Phase 4Aranesp®
Chronic Renal Failure+1 more
Completed—1
Phase 3Panitumumab
Metastatic Colorectal Cancer+9 more
Completed
2010-12-15past
2
Phase 3amg 162
Bone Metastases in Men With Hormone-Refractory Prostate Cancer+2 more
Completed
2012-02past
1
Phase 3Apremilast 20mg
Psoriatic Arthritis
Completed
2012-08-21past
1
Phase 3Cetuximab
Metastatic Colorectal Cancer
Completed
2013-02-05past
1
Phase 3Placebo
Breast Cancer+6 more
Completed
2013-04-05past
4
Phase 3Rilotumumab
Gastric Cancer
Terminated
2014-11past
1
Phase 3RP103
Cystinosis
Completed
2015-02past
1
Phase 3Romozosumab
Postmenopausal Osteoporosis
Completed
2015-05-14past
1
Phase 3Denosumab (CP2)
Postmenopausal Osteoporosis
Completed
2015-07past
1
Phase 3ABP 501
Arthritis, Rheumatoid
Completed
2016-04past
1
Phase 3Interferon γ-1b
Friedreich's Ataxia
Completed
2017-03-21past
1
Phase 3romosozumab HCP administration with PFS
Post-Menopausal Osteoporosis
Completed
2019-04-11past
1
Phase 3Dexamethasone
Relapsed Multiple Myeloma+2 more
Completed
2020-01-16past
2
Phase 3Apremilast
Psoriasis+3 more
Completed
2021-01-27past
4
Phase 3ABP 654
Plaque Psoriasis
Completed
2022-01-13past
1
Phase 3Denosumab
Bone Metastases+8 more
Completed
2022-03-26past
5
Phase 3Ustekinumab
Psoriasis
Completed
2023-02-28past
1
Phase 3Carfilzomib
Multiple Myeloma+4 more
Completed
2023-03-31past
3
Phase 3Evolocumab
Dyslipidemia+2 more
Completed
2025-07-25past
3
Phase 3Erenumab Dose 1
Migraine
Active, not recruiting
2025-11-19past
1
Phase 3Etelcalcetide
Hyperparathyroidism, Secondary+1 more
Recruiting
2027-06-30
2
Phase 2darbepoetin alfa
Anemia+1 more
Completed
2003-06past
1
Phase 2Unnamed
Ovarian Cancer
Completed
2005-04past
1
Phase 2CCX282-B
Celiac Disease+1 more
Completed
2008-08past
2
Phase 2Cisplatin
Head and Neck Cancer+1 more
Completed
2011-03-29past
1
Phase 2AMG 386
Advanced Hepatocellular Carcinoma+1 more
Completed
2011-10past
1
Phase 1Romiplostim
Thrombocytopenic Purpura+1 more
Completed
2013-09-20past
2
Phase 1Talimogene Laherparepvec
Hepatocellular Carcinoma+4 more
Completed
2022-02-14past
2
Phase 1Blinatumomab
Relapsed Refractory B Precursor Acute Lymphoblastic Leukemia+1 more
Completed
2023-01-24past
2
Phase 2HZN-825 BID
Diffuse Cutaneous Systemic Sclerosis+1 more
Terminated
2025-02-24past
1
Phase 2Sotorasib
Non-small Cell Lung Cancer
Completed
2025-05-27past
1
Phase 1Bemarituzumab
Gastric Cancer+2 more
Active, not recruiting
2025-11-21past
2
Phase 2Rocatinlimab
Asthma
Active, not recruiting
2026-10-19
1
Phase 2anvumetostat
MTAP-deleted NSCLC
Active, not recruiting
2026-10-31
1
Phase 1AMG 732
Thyroid Eye Disease
Recruiting
2027-02-22
1
Phase 2Inebilizumab
Neuromyelitis Optica Spectrum Disorder
Recruiting
2027-04-13
1
Phase 2pegfilgrastim
Non-Hodgkin's Lymphoma
Completed—1
Phase 1Unnamed
Healthy Men and Women
Completed
2004-10past
1
Phase 1AMG 403
Osteoarthritis
Completed
2008-01past
1
Phase 1HPN-100
Drug Toxicity
Completed
2010-09past
1
Phase 1CCX168
Vasculitis+1 more
Completed
2010-09-19past
1
Phase 1AMG 208
Cancer+5 more
Completed
2013-02past
1
Phase 1Erenumab
Migraine+1 more
Completed
2014-03-11past
2
Phase 1AMG 811
Nephritis+1 more
Completed
2014-06past
1
Phase 1AMG 986 IV
Heart Failure+1 more
Terminated
2019-04-18past
1
Phase 1VIB7734
Systemic Lupus Erythematosus+5 more
Completed
2020-07-20past
1
Phase 1Teprotumumab
Thyroid Eye Disease
Completed
2023-02-28past
1
Phase 1Olpasiran
Hepatic Impairment
Completed
2023-04-05past
1
Phase 1Tarlatamab
Neuroendocrine Prostate Cancer
Completed
2024-07-22past
1
Phase 1AMG 355
Advanced Solid Tumors
Active, not recruiting
2026-07-21
1
Phase 1COC
Overweight+1 more
Recruiting
2026-10-07
1
Phase 1Xaluritamig
Prostate Cancer+3 more
Recruiting
2026-10-08
2
Phase 1AMG 127
Diabetes Mellitus, Type 2
Not yet recruiting
2027-10-02
1
Phase 1AMG 119
Small Cell Lung Cancer
Suspended
2028-01-14
1
N/AUnnamed
Kidney Transplantation
Completed
2004-09past
1
N/AENBREL®
Rheumatoid Arthritis
Completed
2008-06past
2
N/AUnnamed
Anemia+13 more
Completed
2013-08past
1
N/AUnnamed
Chemotherapy-induced Febrile Neutropenia
Completed
2013-12past
1
N/AUnnamed
Immune Thrombocytopenic Purpura
Completed
2015-11past
1
N/AAMG 162 - Prolia
Post Menopausal Osteoporosis
Completed
2017-10-26past
1
N/AUnnamed
Major Cardiovascular Event+1 more
Recruiting
2028-12-19
1
N/AAMG 510
Non Small-cell Lung Cancer+2 more
No Longer Available—1
Valuation

Risk-adjusted NPV

Loading pipeline…
Peer comparison

Cohort check

Large-cap biotech · 5 tickers
Loading peers…
Cells tinted green are top-ranked in the cohort, red are worst-ranked.